SEC Form 4 · accession 0001231919-26-000838
Attovia Therapeutics, Inc. · ATTO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
FHMLS XI, L.P.
10% Owner
Frazier Life Sciences XI, L.P.
10% Owner
FHMLS XI, L.L.C.
10% Owner
Period of report
Aug 6, 2026
Accepted (ET)
Aug 6, 2026 · 5:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002058707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 6, 2026 | C | 1,749,192 | — | A | 1,824,541 | D | |
| Common StockF3,F2 | Aug 6, 2026 | C | 1,590,175 | — | A | 3,414,716 | D | |
| Common StockF4,F2 | Aug 6, 2026 | C | 1,189,940 | — | A | 4,604,656 | D | |
| Common StockF5,F2 | Aug 6, 2026 | C | 961,322 | — | A | 5,565,978 | D | |
| Common StockF2 | Aug 6, 2026 | P | 588,235 | $17.00 | A | 6,154,213 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A-1 Preferred StockF2,F1 | — | Aug 6, 2026 | C | 16,250,000 | D | — | — | Common Stock | 1,749,192 | 0 | D |
| Series A-2 Preferred StockF2,F3 | — | Aug 6, 2026 | C | 14,772,727 | D | — | — | Common Stock | 1,590,175 | 0 | D |
| Series B Preferred StockF2,F4 | — | Aug 6, 2026 | C | 11,054,544 | D | — | — | Common Stock | 1,189,940 | 0 | D |
| Series C Preferred StockF2,F5 | — | Aug 6, 2026 | C | 8,930,685 | D | — | — | Common Stock | 961,322 | 0 | D |
Explanation of responses
- F1The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
- F2The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.
- F3The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
- F4The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
- F5The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.